title: The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration.
abstract: We previously demonstrated that the CNYYSNS peptide derived from tumstatin inhibited in vivo tumor progression. The YSNS motif formed a beta-turn crucial for biological activity. More recently, a YSNSG cyclopeptide with a constrained beta-turn on the YSNS residues was designed. Intraperitoneal administration of the YSNSG cyclopeptide inhibited in vivo melanoma progression more efficiently than the native linear peptide. In the present article, we showed that the YSNSG cyclopeptide also triggered an inhibition of in vivo tumor neovascularization and we further analyzed its in vitroantiangiogenic effect. The YSNSG cyclopeptide did not alter endothelial cell proliferation but inhibited cell migration by 83% in an in vitro wound healing model. The inhibition was mediated by a decrease in active MT1-MMP at the migration front as well as a decrease in u-PA and u-PAR expression. The cyclopeptide also altered beta1-integrin distribution in endothelial cell lamellipodia, induced a strong decrease in the phosphorylated focal adhesion kinase (p125(FAK)), disorganized F-actin stress fibers and decreased the number of lamellipodia, resulting in a non migratory phenotype. Our results confirm the YSNSG cyclopeptide as a potent antitumor agent, through both the inhibition of invasive properties of tumor cells and the antiangiogenic activity.
authors: CNRS UMR 6237, Université de Reims Champagne-Ardenne, CHU de Reims, Reims, France.
authors: Jessica
authors: J
authors: Thevenard
authors: Laurent
authors: L
authors: Ramont
authors: Jérome
authors: J
authors: Devy
authors: Bertrand
authors: B
authors: Brassart
authors: Aurélie
authors: A
authors: Dupont-Deshorgue
authors: Nicolas
authors: N
authors: Floquet
authors: Laurence
authors: L
authors: Schneider
authors: Farid
authors: F
authors: Ouchani
authors: Christine
authors: C
authors: Terryn
authors: François-Xavier
authors: FX
authors: Maquart
authors: Jean-Claude
authors: JC
authors: Monboisse
authors: Sylvie
authors: S
authors: Brassart-Pasco
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001324:Autoantigens / Q000737:chemistry; D015153:Blotting, Western; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D024141:Collagen Type IV / Q000737:chemistry; D015536:Down-Regulation; D042783:Endothelial Cells / Q000187:drug effects*; D005455:Fluorescent Antibody Technique; D006801:Humans; D007150:Immunohistochemistry; D053511:Matrix Metalloproteinase 14 / Q000187:drug effects / Q000378:metabolism; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010456:Peptides, Cyclic / Q000494:pharmacology*; D055293:Receptors, Urokinase Plasminogen Activator / Q000187:drug effects / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000187:drug effects / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D001324:Autoantigens; D024141:Collagen Type IV; D010456:Peptides, Cyclic; D055293:Receptors, Urokinase Plasminogen Activator; C521292:YSNSG cyclopeptide; C057112:type IV collagen alpha3 chain; D014568:Urokinase-Type Plasminogen Activator; D053511:Matrix Metalloproteinase 14